Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina
NCT04738435 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2021-08-25
Summary
The main of the study is to describe the incidence in health personnel who present events supposedly attributed to vaccines and immunizations after having received the two components of the Sputnik V vaccine, with the information obtained thanks to the participation of health workers in actively reporting their health status.
Conditions
Sponsors & Collaborators
-
Ministerio de Salud de Ciudad Autónoma de Buenos Aires
collaborator OTHER_GOV -
Hospital Italiano de Buenos Aires
lead OTHER
Principal Investigators
-
Vanina pagotto, Msc · Hospital Italiano de Buenos Aires
-
Silvana Figar, Msc · Hospital Italiano de Buenos Aires
-
Mercedes Soriano · Hospital Italiano de Buenos Aires
-
Analia Ferloni, MD · Hospital Italiano de Buenos Aires
-
Valeria Aliperti, Msc · Hospital Italiano de Buenos Aires
-
Morena Diaz · Hospital Italiano de Buenos Aires
-
Nahuel Braguisnky · Hospital Italiano de Buenos Aires
-
Maria Isabel González · Hospital Italiano de Buenos Aires
-
Maria Ines Staneloni, MD · Hospital Italiano de Buenos Aires
-
Valeria Asprea, MD · Hospital Italiano de Buenos Aires
-
Paula Zingoni, MD · Ministry of Health of the Government of the City of Buenos Aires
-
Hernan Michelangelo, MD · Hospital Italiano de Buenos Aires
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-01-05
- Primary Completion
- 2021-03-01
- Completion
- 2021-03-01
Countries
- Argentina
Study Locations
More Related Trials
-
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
NCT05037097 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19
NCT04780035 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
NCT03843632 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
NCT04885361 ·Status: UNKNOWN ·Phase: PHASE1
-
Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes
NCT04962906 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity
NCT04789356 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety of a Second Dose of Biken's Varicella Vaccine
NCT00830648 ·Status: COMPLETED ·Phase: PHASE4
-
Flucelvax (TIVc or QIVc) Pregnancy Registry
NCT03438487 ·Status: COMPLETED
-
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
NCT05233826 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Sputnik V COVID-19 Vaccination in Adults in Kazakhstan
NCT04871841 ·Status: COMPLETED
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Assessing Immune Response of Different COVID-19 Vaccines in Older Adults
NCT05160766 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
NCT05933512 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults
NCT03051386 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
NCT04756830 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers
NCT04795414 ·Status: UNKNOWN
-
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
NCT05703607 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19
NCT04844268 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
NCT05472038 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
NCT04895982 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)
NCT05087368 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
NCT07069309 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
NCT03368495 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
NCT05463068 ·Status: COMPLETED ·Phase: PHASE3
-
Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.
NCT05228912 ·Status: COMPLETED